The complete list of Bristol-Myers Squibb and Pfizer Alliance presentations is included below.
#Apixaban antidote trial
“This year at ESC Congress 2016, we’ll be discussing new NVAF and VTE data that complement our robust body of clinical trial data.” Guidelines for Reversal of Anticoagulation. “As patient and provider needs continue to evolve, it’s essential that we deepen our understanding of how medicines are working in real-world situations,” said Jack Lawrence, M.D., Vice President, Cardiovascular Specialty Development, Bristol-Myers Squibb. 11 with peak levels of approximately 200 ng/mL showed an important reversal effect only for 270 g/kg rFVIIa, supporting our findings in this and a previous study of our group. An in vitro investigation by Escolar et al. “We look forward to the opportunity to contribute to the scientific discussion and continued research during ESC Congress 2016.” Case reports of PCC use for apixaban reversal describe differing efficacy 23, 24 for apixaban reversal in clinical settings. “The Bristol-Myers Squibb and Pfizer Alliance is pleased to share 19 abstracts, which include new real-world analyses, as well as new sub-analyses from the pivotal Phase 3 ARISTOTLE trial,” said Rory O’Connor, M.D., Chief Medical Officer, Internal Medicine, Pfizer Innovative Health. Of note, several of the real-world data analyses are part of ACROPOLIS™ ( A pixaban Experien C e Through R eal-W O rld PO pu L at I on S tudies), a global real-world data research program designed to further evaluate the effectiveness and safety of apixaban in routine clinical practice.
These new data from post-hoc analyses from ARISTOTLE ( A pixaban for R eduction I n ST roke and O ther T hromboembo L ic E vents in Atrial Fibrillation) and retrospective real-world data analyses continue to underscore the Alliance’s commitment to the evaluation of Eliquis for patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). EMA’s human medicines committee has recommended granting a conditional marketing authorisation in the European Union for Ondexxya (andexanet alfa). (NYSE: PFE) announced today that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at ESC Congress 2016, to be held August 27–31 in Rome, Italy.
0 kommentar(er)
